- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06112340
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
October 31, 2023 updated by: Sling Therapeutics, Inc.
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24.
These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
75
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cathy Radovich
- Phone Number: 734-887-9192
- Email: info@slingtx.com
Study Contact Backup
- Name: Robin Schmidt
- Phone Number: 734-887-9192
- Email: info@slingtx.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Bascom Palmer Eye Institute
-
Contact:
- Jennifer Gomez
- Email: jxg1540@miami.edu
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Recruiting
- West Virginia University Eye Institute
-
Contact:
- Athena Echols
- Email: athena.sparks@wvumedicine.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (< 2 mm reduction in proptosis in the study eye) at Week 24 of VGN-TED-301 study or proptosis responders at Week 24 who relapse during the Follow-Up period of VGN-TED-301
- Subject has not received any treatment for TED since Week 24 of VGN-TED-301
- Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine levels [FT3] <50% above or below the normal limits) at Baseline. Every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial
- Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not planning for any such treatment during the course of the study
Exclusion Criteria:
- The exclusion criteria of protocol VGN-TED-301 also apply to this extension study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Low Dose
Active Arm Low Dose Linsitinib
|
Study medication taken twice daily by mouth
|
Active Comparator: High Dose
Active Arm High Dose Linsitinib
|
Study medication taken twice daily by mouth
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects who are Proptosis Responders at Week 24
Time Frame: 24 weeks
|
Percentage of subjects with a ≥ 2 mm reduction of proptosis from baseline as determined by exophthalmometer
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects who are CAS Categorical Responders at Week 24 (Study Eye)
Time Frame: 24 weeks
|
24 weeks
|
|
Change from Baseline in Proptosis to Week 24 (Study Eye)
Time Frame: 24 weeks
|
Change from baseline in reduction of proptosis from baseline as determined by exophthalmometer
|
24 weeks
|
Percentage of Subjects who are Overall Responders at Week 24
Time Frame: 24 weeks
|
Percentage of Subjects with a response of ≥ 2 mm reduction of proptosis at Week 24 as determined by exophthalmometer
|
24 weeks
|
Change from Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 11, 2023
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
October 16, 2023
First Submitted That Met QC Criteria
October 31, 2023
First Posted (Actual)
November 1, 2023
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 31, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VGN-TED-302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eye Diseases
-
University of Alabama at BirminghamPfizerCompletedVision | Eye Disease | Eye CareUnited States
-
TBF Genie TissulaireCompletedEnucleated; Eye | Eye CancerFrance
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
National Eye Institute (NEI)RecruitingInherited Eye DiseaseUnited States, United Kingdom, China, Pakistan, Philippines, Ukraine, India, Italy
-
National Eye Institute (NEI)Recruiting
-
National Eye Institute (NEI)RecruitingGenetic Eye DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
OptovueCompletedNo Eye DiseaseUnited States, United Kingdom
Clinical Trials on linsitinib
-
Sling Therapeutics, Inc.RecruitingEye Diseases | Endocrine System Diseases | Thyroid Diseases | Thyroid Eye Disease | Graves Ophthalmopathy | Exophthalmos | Orbital Diseases | Thyroid Associated Ophthalmopathy | Graves Orbitopathy | Proptosis | IGF1R | HashimotoUnited States, Spain, Canada, Italy, United Kingdom
-
University of OxfordAstellas Pharma Inc; European Organisation for Research and Treatment of Cancer... and other collaboratorsCompletedRefractory Ewing Sarcoma | Relapsed Ewing SarcomaUnited Kingdom, Germany, Netherlands, Italy, France
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
Astellas Pharma IncCompletedAdrenocortical CarcinomaUnited States, France, Netherlands, Italy, Canada, Germany, Australia, Poland, United Kingdom
-
National Cancer Institute (NCI)CompletedChondrosarcoma | Gastrointestinal Stromal Tumor | Paraganglioma | Carney ComplexUnited States
-
University of Colorado, DenverTerminated
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnSquamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Squamous Cell Carcinoma of the...United States
-
National Cancer Institute (NCI)CompletedRecurrent Small Cell Lung CarcinomaUnited States, Singapore
-
Astellas Pharma Global Development, Inc.CompletedAdvanced Solid TumorsGermany, Czechia, United States, Brazil, Poland, Singapore, Thailand